Abstract
<jats:p>Drug–drug interactions between biotech and small-molecule drugs play a critical role in medication safety and therapeutic efficacy. However, most existing computational DDI prediction methods focus primarily on interactions between small-molecule drugs, leaving biotech–small-molecule interactions comparatively underexplored. In this study, we propose B-SMART-Former, an explainable deep learning framework for predicting interaction types between biotech and small-molecule drugs. The proposed framework integrates ChemBERTa embeddings and Morgan molecular fingerprints for small molecules with ProtBERT embeddings for biotech drugs, eliminating the need for similarity-based features while leveraging complementary molecular representations. These multimodal features are processed by a hybrid architecture that combines Transformer-based self-attention, residual convolutional learning, and a multi-layer perceptron classifier to capture both global contextual dependencies and local discriminative patterns. The model is formulated as a multi-class classification task and evaluated using stratified 10-fold cross-validation. To improve model transparency, Integrated Gradients is employed as a post-hoc explainability method to identify the molecular features that contribute most strongly to each prediction. Experimental results demonstrate that B-SMART-Former achieves a micro-averaged AUROC of 0.9978 and an AUPR of 0.9682 while relying solely on intrinsic molecular representations, remaining competitive with similarity-based approaches. The proposed framework offers an effective and explainable solution for biotech–small-molecule DDI prediction and provides a practical foundation for future computational drug interaction studies.</jats:p>